前沿生物药业（南京）股份有限公司2025年第三次临时股东大会决议公告

Group 1 - The company held its third extraordinary general meeting of shareholders on November 19, 2025, where several key resolutions were passed [9][10] - The meeting confirmed the cancellation of the supervisory board and the transfer of its responsibilities to the audit committee of the board of directors [10] - The company will maintain a board of directors consisting of seven members, including three non-independent directors, three independent directors, and one employee director [10] Group 2 - All proposed resolutions were approved without any dissenting votes [2][4] - The resolutions included amendments to the company's articles of association and governance systems, as well as the abolishment of the supervisory board meeting rules [5][10] - The meeting was legally witnessed by Beijing Guofeng (Nanjing) Law Firm, confirming that the procedures followed were in compliance with relevant laws and regulations [6]